Enterprise Value
324.8M
Cash
140.8M
Avg Qtr Burn
-19.15M
Short % of Float
22.76%
Insider Ownership
1.02%
Institutional Own.
68.11%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Non-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Phase 2 Update | ||
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Type 2 diabetes | Phase 1b Update | |
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued | |
NasoVAX Details Influenza | Failed Discontinued | |
AdCOVID Details COVID-19 | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued | |
T-COVID Details COVID-19 | Failed Discontinued |